Engineering the Future of Tear-Based Molecular Diagnostics
BioDrop is developing an integrated tear-biopsy platform that combines biomaterial engineering, molecular preservation, advanced laboratory analysis, and artificial intelligence to unlock the diagnostic potential of tear-derived biomarkers. By enabling standardized collection and preservation at the point of care—or at home—our technology is designed to support scalable, non-invasive precision diagnostics.
Standardized collection of tear-derived biomarkers
Preservation of molecular integrity during transport
Compatibility with advanced molecular analysis
Designed for future AI-assisted diagnostics
Non-invasive and patient-friendly workflow
We are building the infrastructure that enables tear biopsy to become a practical platform for precision diagnostics.
Our proprietary hydrogel technology is designed to gently collect tear fluid while preserving fragile molecular biomarkers during sampling and transport. This enables downstream molecular analyses—including microRNA profiling and future multi-omics applications—using a simple, non-invasive workflow.
A New Approach to Molecular Sampling
Every tear carries a molecular story. Our mission is to learn how to read it.
A Full System, Not Just a Lens
BioDrop is developing an integrated tear-biopsy platform that brings together standardized sample collection, biomarker preservation, molecular analysis, and computational interpretation within a unified diagnostic workflow.
Rather than focusing on a single collection device, we are building technologies that enable the complete journey from biomarker acquisition to clinically meaningful molecular insight.
Building the Future of Tear Biopsy
BioDrop is advancing an integrated platform for non-invasive molecular diagnostics that combines innovative biomaterials, standardized biomarker preservation, advanced molecular analysis, and computational intelligence.
Our initial focus is neuro-oncology, where earlier access to molecular information may improve clinical decision-making. As the platform evolves, its applications are intended to expand across neurological, oncological, ophthalmological, and systemic diseases.
We believe that the future of precision medicine depends not only on discovering new biomarkers, but on making them reliably accessible through standardized, scalable, and patient-friendly technologies.
BioDrop is building more than a diagnostic technology. We are creating a platform designed to simplify how molecular information is collected, preserved, and transformed into clinically meaningful insight.
Our vision is a future in which advanced molecular diagnostics become more accessible, less invasive, and easier to integrate into everyday clinical care—bringing precision medicine closer to patients worldwide.
We believe the next breakthrough in precision medicine will come not only from discovering new biomarkers, but from transforming how they are collected, preserved, and interpreted.
Our initial scientific focus is neuro-oncology, while the underlying platform is designed to support future applications across neurological, ophthalmological, oncological, and systemic diseases.